^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Mediastinal B Cell Lymphoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated:...for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy....KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.
